Combination antiretroviral therapy and incidence of AIDS-related malignancies

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 4 SUPPL., 1999, Pages

  Buchbinder, Susan P ^a,d   Holmberg, Scott D ^b   Scheer, Susan ^a   Colfax, Grant ^a   O'Malley, Paul ^a   Vittinghoff, Eric ^c  

^a HIV Research Section   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (United States)

Author keywords

AIDS incidence; Combination antiretroviral therapy; HAART; HIV incidence; Kaposi's sarcoma; Lymphoma

Indexed keywords

ANTIVIRUS AGENT;

AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; CANCER INCIDENCE; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG THERAPY, COMBINATION; HUMANS; INCIDENCE; LYMPHOMA; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; PREVALENCE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033179063     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Update: trends in AIDS incidence - United States, 1996. MMWR 1997;46:861-7.
2. Hogg RS, O'Shaughnessy MV, Gataric N, Vip B, Craib K, Schechter MT, Montaner JS. Decline in deaths from AIDS due to new anti-retrovirals [letter]. Lancet 1997;349(9061):1294.
3. Hessol NA, Koblin BA, van Griensven GJ, et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol 1994;139(11):1077-87.
4. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination anti-retroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999;179: 717-20.
5. Oskenhendler E, Clauvel JP, Jouveshomme S, Davi F, Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy [letter]. Am J Hematol 1998:57:266.
6. Aboulafia DM. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clinic Proc 1998;73:439-43.
7. Wit FW, Sol CJ, Renwick N, et al. Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy [letter]. AIDS 1998;12:218-9.
8. Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor [letter]. AIDS 1997;11:261-2.
9. Kedes DH, Lagunoff M, Renne R, Ganem D. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J Clin Invest 1997;100 (10):2606-10.
10. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
11. Gao SJ, Kinglsey L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996;335:233-41.
12. Mallery SR, Landwehr DJ, Ness GM, Clark YM, Hoh CM. Thiol redox modulation of tumor necrosis factor-alpha responsiveness in cultured AIDS-related Kaposi's sarcoma cells. J Cell Biochem 1998;68:339-54.
13. + T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998;14 (7):561-9.
14. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998;177 (4):898-904.
15. Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16(5):318-26.
16. Schnittman SM, Fox L. Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases. AIDS Res Hum Retroviruses 1997;13 (10):815-8.
17. Bacchetti P, Moss AR. Incubation period of AIDS in San Francisco. Nature 1989;338(6212):251-3.
18. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. New Engl J Med 1998;338(14):948-54.
19. Winkelstein W Jr, Samuel M, Padian NS, et al. The San Francisco Men's Health Study. III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-86. Am J Public Health 1987;77(6):685-9.
20. Winkelstein W Jr, Wiley JA, Padian NS, et al. The San Francisco Men's Health Study: continued decline in HIV seroconversion rates among homosexual/bisexual men. Am J Public Health 1988; 78(11):1472-4.
21. Levine AM, Bernstein L, Sullivan-Halley J, Shibata D, Mahterian SB, Nathwani BN. Role of zidovudine antiretroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma. Blood 1995;86:4612-6.
22. Widney D, Yawetz S, van der Meyden M, Miles SA, Hishimoto T, Martinez-Maza O. Effects of zidovudine on B lymphocyte activation. Cell Immunol 1994;158:140-56.
23. Przybylski GK, Goldman J, Ng VL, et al. Evidence for early B-cell activation preceding the development of Epstein-Barr virus-negative acquired immunodeficiency syndrome-related lymphoma. Blood 1996;88:4620-9.
24. Monroe JG, Silberstein LE. HIV-mediated B-lymphocyte activation and lymphomagenesis. J Clin Immunol 1995;15:61-8.
25. Sharma V, Walper D, Deckert R. Modulation of macrophage inflammatory protein-1 alpha and its receptors in human B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma. Biochem Biophys Res Commun 1997; 235:576-81.
26. Marfaing-Koka A, Aubin JT, Grangeot-Keros L, et al. In vivo role of IL-6 on the viral load and on immunologic abnormalities of HIV infected patients. J Acquir Immune Defic Syndr 1996:11:59-68.
27. Moore PS, Boshoff C, Weiss RA, Change Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996;274:1739-44.
28. Knowles DM. Molecular pathology of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Semin Diagn Pathol 1997;14:67-82.
29. Ng VL, Hurt MH, Herndier BG, Fr KE, McGrath MS. VH gene use by HIV type-1-associated lymphoproliferations. AIDS Res Hum Retroviruses 1997:13:135-49.
30. Herndier BG, Kaplan LD, McGrath MS. Pathogenesis of AIDS lymphomas. AIDS 1994;8:1025-49.